MedPath
HSA Approval

NEBIPRESS TABLETS 5MG

SIN16976P

NEBIPRESS TABLETS 5MG

NEBIPRESS TABLETS 5MG

March 22, 2024

NOVEM HEALTHCARE PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNOVEM HEALTHCARE PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

C07AB12

nebivolol

Manufacturer Information

NOVEM HEALTHCARE PTE LTD

2nd Plant, Standard Chem. & Pharm. Co. Ltd.

Active Ingredients

Nebivolol Hydrochloride eqv. to Nebivolol

5 mg

Nebivolol

Documents

Package Inserts

NEBIPRESS TABLETS 5MG PI.rtf

Approved: March 22, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

NEBIPRESS TABLETS 5MG - HSA Approval | MedPath